▪ Data from the monkey challenge study published in Nature Communications showed a single dose of neutralizing antibody ABP 300 blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting
▪ Safety demonstrated in non-human primates
▪ ABP 300 showed the potential to neutralize eight SARS-CoV-2 strains with reported high-frequency mutations
▪ Data support the continued evaluation of neutralizing antibody therapeutic, ABP 300, in human subjects
WOBURN, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) — Abpro Corporation today announced the publication of a peer-reviewed article in the scientific journal Nature Communications titled, “Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.” The publication is available online here.
ABP 300, referred to as MW05 in the publication, neutralizes COVID-19 by binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, blocking the viral interaction with the angiotensin-converting enzyme 2 (ACE2) receptors of host which are critical for viral entry and infection. Through this mechanism of action, ABP 300 not only completely and safely neutralizes COVID-19 in animal models but could potentially do so with superior safety and efficacy than other monoclonal antibodies in development.
“We are highly encouraged by this preclinical best-in-class proof-of-concept data showing the potential of our monoclonal antibodies to neutralize multiple SARS-CoV-2 strains. The data supports further development of antibody-based therapies for prophylactic and therapeutic treatment of COVID-19,” said Ian Chan, chief executive officer and co-founder of Abpro Corporation. “As the SARS-CoV-2 mutates, which could undermine the effectiveness of vaccines and therapies, there is an urgent need for treatments that can address a broad range of strains.”
Study highlights:
About ABP 300
ABP 300 is a human neutralizing monoclonal antibody therapy against COVID-19 that was created using the latest technologies available for antibody discovery. ABP 300 disrupts the interaction of the viral receptor binding domain (RBD) with host angiotensin-converting enzyme 2 (ACE2) receptor and has shown neutralizing efficacy in vivo against COVID-19 by blocking viral entry into cells. ABP 300 recently completed a Phase 1 dose escalation study in human subjects.
About Abpro
Abpro Corporation is a clinical stage biotechnology company located in Woburn, Massachusetts. The Company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro’s DiversImmune™ platform has been used successfully against 300 traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas. For more information, please visit www.abpro.com.
Media Contact
Michael Tattory
LifeSci Communications
1 (646) 751-4362
mtattory@lifescicomms.com
Toronto, Ontario--(Newsfile Corp. - January 9, 2025) - Align Wellness launches a new partnership opportunity…
Calgary, Alberta--(Newsfile Corp. - January 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE:…
Britannia selling its UK lab and testing business to a private UK-based acquiror for total…
New independent directors Christof Bircher and Nneka Ukpai bring significant expertise in business strategy, corporate…
Exclusive Distributor to Drive International Growth in Chile, Argentina, Peru and Colombia LOS ANGELES, CA…
Three customers take delivery at year endVANCOUVER, BC / ACCESSWIRE / January 9, 2025 /…